PROCORE TECHNOLOGIES, INC.·4

Apr 14, 8:46 PM ET

Courtemanche Craig F. Jr. 4

4 · PROCORE TECHNOLOGIES, INC. · Filed Apr 14, 2026

Research Summary

AI-generated summary of this filing

Updated

Procore (PCOR) Chairman Craig Courtemanche Exercises Options, Sells Shares

What Happened

  • Craig F. Courtemanche Jr., Director and Chairman of the Board of Procore Technologies (PCOR), exercised 56,122 options on 2026-04-10 at $2.42 per share (cost $135,815) and immediately sold the same 56,122 shares in three open-market transactions that day for aggregate proceeds of $2,673,528. Net proceeds after exercise cost were roughly $2.54M.
  • The sales were executed under a pre-established 10b5-1 plan dated December 9, 2025.

Key Details

  • Transaction date: April 10, 2026; Form 4 filed April 14, 2026 (timely filing).
  • Exercise: 56,122 shares acquired at $2.42 each (total $135,815).
  • Sales (open market): 48,465 shares @ weighted $47.45 (proceeds $2,299,664); 4,922 shares @ weighted $48.43 (proceeds $238,372); 2,735 shares @ weighted $49.54 (proceeds $135,492). Total proceeds $2,673,528.
  • Price ranges: sales executed across price ranges of $47.08–$47.90, $48.08–$49.03, and $49.12–$49.745 (weighted averages reported; per-footnotes, detailed breakdowns available on request).
  • Shares owned after the transactions are not specified in the provided filing excerpt.
  • Related notes: several holdings referenced as held in family trusts (per filing footnotes) and the exercised option was subject to a long-term vesting schedule detailed in the filing.

Context

  • This was effectively a cashless exercise: options were exercised and the resulting shares were sold the same day. Such transactions are often routine liquidity events, especially when done under a 10b5-1 plan; they do not by themselves indicate a change in insider sentiment.
  • The 10b5-1 plan and the exercise/sale timing reduce the likelihood that the trades were opportunistic based on nonpublic information, but investors should interpret insider sales cautiously and consider them alongside other insider activity and company fundamentals.

Insider Transaction Report

Form 4
Period: 2026-04-10
Transactions
  • Exercise/Conversion

    Common Stock

    2026-04-10$2.42/sh+56,122$135,815983,702 total
  • Sale

    Common Stock

    [F1][F2]
    2026-04-10$47.45/sh48,465$2,299,664935,237 total
  • Sale

    Common Stock

    [F1][F3]
    2026-04-10$48.43/sh4,922$238,372930,315 total
  • Sale

    Common Stock

    [F1][F4]
    2026-04-10$49.54/sh2,735$135,492927,580 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F8]
    2026-04-10$2.42/sh56,122$135,815336,732 total
    Exercise: $2.42Exp: 2026-11-10Common Stock (56,122 underlying)
Holdings
  • Common Stock

    [F5]
    (indirect: See Footnote)
    2,692,461
  • Common Stock

    [F6]
    (indirect: See Footnote)
    1,155,480
  • Common Stock

    [F7]
    (indirect: See Footnote)
    527,349
  • Common Stock

    (indirect: By Spouse)
    23,736
Footnotes (8)
  • [F1]These shares sold pursuant to a 10b5-1 plan dated December 9, 2025.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $47.08 to $47.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $48.08 to $49.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $49.12 to $49.745, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]These shares are held by the Craig F. Courtemanche and Hillary Courtemanche Family Trust dated as of November 1, 2012.
  • [F6]These shares are held by the Courtemanche 2021 Irrevocable Trust UA DTD 6/10/2021.
  • [F7]These shares are held by The Courtemanche 2016 Irrevocable Trust.
  • [F8]The shares subject to the option vested in 60 equal monthly installments beginning on the one month anniversary of February 5, 2016, subject to continued service through each applicable vesting date.
Signature
/s/ Benjamin C. Singer, Attorney-in-Fact|2026-04-14

Documents

1 file
  • 4
    wk-form4_1776214013.xmlPrimary

    FORM 4